26 Nov 2025 by admin in UncategorizedComments Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
19 Nov 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
17 Nov 2025 by admin in UncategorizedComments NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
23 Oct 2025 by admin in UncategorizedComments Sail Biomedicines Appoints Martin Mackay, Ph.D., to Its Board of Directors
16 Oct 2025 by admin in UncategorizedComments NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
16 Oct 2025 by admin in UncategorizedComments Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment- Refractory Rheumatoid Arthritis (RA)
08 Oct 2025 by admin in UncategorizedComments Zenas BioPharmand InoCare Pharma Anounce License Agrement Granting Zenas Rights for Thre Autoimune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
07 Oct 2025 by admin in UncategorizedComments Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
22 Sep 2025 by admin in UncategorizedComments Avenzo Therapeutics Announces $60 Million Series B Financing
10 Sep 2025 by admin in UncategorizedComments Design Therapeutics Appoints Justin Gover to Board of Directors
